Cargando…

Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients

BACKGROUND AND PURPOSE: The aim of this study was to elucidate the clinical features, prothrombotic risk factors, and outcome of pediatric Moyamoya patients. METHODS: Patients diagnosed with Moyamoya disease at a tertiary center between January 2000 and December 2006 were enrolled in this study. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatlı, Burak, Ekici, Barış, Sencer, Altay, Sencer, Serra, Aydın, Kubilay, Aydınlı, Nur, Çalışkan, Mine, Özmen, Meral, Kırış, Talat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391613/
https://www.ncbi.nlm.nih.gov/pubmed/22787492
http://dx.doi.org/10.3988/jcn.2012.8.2.100
_version_ 1782237523697729536
author Tatlı, Burak
Ekici, Barış
Sencer, Altay
Sencer, Serra
Aydın, Kubilay
Aydınlı, Nur
Çalışkan, Mine
Özmen, Meral
Kırış, Talat
author_facet Tatlı, Burak
Ekici, Barış
Sencer, Altay
Sencer, Serra
Aydın, Kubilay
Aydınlı, Nur
Çalışkan, Mine
Özmen, Meral
Kırış, Talat
author_sort Tatlı, Burak
collection PubMed
description BACKGROUND AND PURPOSE: The aim of this study was to elucidate the clinical features, prothrombotic risk factors, and outcome of pediatric Moyamoya patients. METHODS: Patients diagnosed with Moyamoya disease at a tertiary center between January 2000 and December 2006 were enrolled in this study. The clinical presentations, underlying diseases, prothrombotic risk factors, family history of thrombosis, radiological findings, treatment, and outcome of the patients were reviewed retrospectively. RESULTS: Eight patients with angiographically proven Moyamoya disease were identified, one of whom had neurofibromatosis type I and one had Down syndrome. The age at diagnosis varied between 19 months and 11 years (73.4±41.8 months, mean±SD). The follow-up period after diagnosis was 52.5±14.8 months. In six patients, the initial clinical presentation was hemiparesis. None of the patients had any identifiable prothrombotic factors. Despite medical and surgical treatment, three patients had recurrences and one died. Only two patients recovered without sequelae. CONCLUSIONS: The value of prothrombotic risk factor evaluation appears to be limited in Moyamoya patients; the outcome for pediatric patients remains dismal.
format Online
Article
Text
id pubmed-3391613
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-33916132012-07-11 Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients Tatlı, Burak Ekici, Barış Sencer, Altay Sencer, Serra Aydın, Kubilay Aydınlı, Nur Çalışkan, Mine Özmen, Meral Kırış, Talat J Clin Neurol Original Article BACKGROUND AND PURPOSE: The aim of this study was to elucidate the clinical features, prothrombotic risk factors, and outcome of pediatric Moyamoya patients. METHODS: Patients diagnosed with Moyamoya disease at a tertiary center between January 2000 and December 2006 were enrolled in this study. The clinical presentations, underlying diseases, prothrombotic risk factors, family history of thrombosis, radiological findings, treatment, and outcome of the patients were reviewed retrospectively. RESULTS: Eight patients with angiographically proven Moyamoya disease were identified, one of whom had neurofibromatosis type I and one had Down syndrome. The age at diagnosis varied between 19 months and 11 years (73.4±41.8 months, mean±SD). The follow-up period after diagnosis was 52.5±14.8 months. In six patients, the initial clinical presentation was hemiparesis. None of the patients had any identifiable prothrombotic factors. Despite medical and surgical treatment, three patients had recurrences and one died. Only two patients recovered without sequelae. CONCLUSIONS: The value of prothrombotic risk factor evaluation appears to be limited in Moyamoya patients; the outcome for pediatric patients remains dismal. Korean Neurological Association 2012-06 2012-06-29 /pmc/articles/PMC3391613/ /pubmed/22787492 http://dx.doi.org/10.3988/jcn.2012.8.2.100 Text en Copyright © 2012 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Tatlı, Burak
Ekici, Barış
Sencer, Altay
Sencer, Serra
Aydın, Kubilay
Aydınlı, Nur
Çalışkan, Mine
Özmen, Meral
Kırış, Talat
Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients
title Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients
title_full Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients
title_fullStr Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients
title_full_unstemmed Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients
title_short Clinical Features, Prothrombotic Risk Factors, and Long-Term Follow-Up of Eight Pediatric Moyamoya Patients
title_sort clinical features, prothrombotic risk factors, and long-term follow-up of eight pediatric moyamoya patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391613/
https://www.ncbi.nlm.nih.gov/pubmed/22787492
http://dx.doi.org/10.3988/jcn.2012.8.2.100
work_keys_str_mv AT tatlıburak clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT ekicibarıs clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT senceraltay clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT sencerserra clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT aydınkubilay clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT aydınlınur clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT calıskanmine clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT ozmenmeral clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients
AT kırıstalat clinicalfeaturesprothromboticriskfactorsandlongtermfollowupofeightpediatricmoyamoyapatients